{"title": "In GSK's trial of shingles vaccine in China, Shingrix keeps it 100", "author": "Kevin Dunleavy", "url": "https://www.fiercepharma.com/pharma/gsks-trial-shingles-vaccine-china-shingrix-keeps-it-100", "hostname": "fiercepharma.com", "description": "In October of last year, GSK laid out a plan to double its business in China by 2025, with much of that expansion dependent upon the succe | In October of last year, GSK laid out a plan to double its business in China by 2025, with much of that expansion dependent upon the success of shingles vaccine Shingrix. On Wednesday, GSK left little doubt about the benefit of Shingrix as it reported 100% efficacy from a post-licensing trial of the shot.", "sitename": "FiercePharma", "date": "2023-08-23", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}